Natco Pharma Ltd. Financials: Quarterly Results
Revenue
816.9
Cr.
PAT
233.30
Cr.
EBITDA
155
Cr.
Natco Pharma Ltd. Q4FY26 Financial Metrics
| Indicator | Mar-26 | Dec-25 | Sep-25 | Jun-25 | Mar-25 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 739.10 | 647.30 | 1363 | 1328.90 | 1221 |
| Total Income From Operations (Cr.) | 739.10 | 647.30 | 1363 | 1328.90 | 1221 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | 155 | 170.60 | 626.80 | 575.10 | 516.10 |
| P/L Before Exceptional Items & Tax (Cr.) | 144.10 | 161.10 | 613.70 | 571.90 | 505.90 |
| P/L After Tax from Ordinary Activities (Cr.) | 233.30 | 140.40 | 517.90 | 480.30 | 406 |
| Net Profit/Loss For the Period (Cr.) | 233.30 | 140.40 | 517.90 | 480.30 | 406 |
| Basic EPS | 14.96 | 8.46 | 28.94 | 26.84 | 22.70 |
FAQs
Natco Pharma Ltd. announced its quarterly results for Q4 FY2026 on May 29, 2026.
In Q4 FY2026, Natco Pharma Ltd. are as follows:
Revenue: ₹816.9 crore
Net Profit: ₹233.30 crore.
For Q4 FY2026, Natco Pharma Ltd. posted ₹816.9 crore in revenue and ₹233.30 crore in net profit.
Past quarterly results for Natco Pharma Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.